Command Palette

Search for a command to run...

Clinical Trials · NCT04057261

Effect of Liraglutide on the Metabolic Profile in Patients With Type 2 Diabetes and Cardiovascular Disease

WithdrawnPhase 3Liraglutide (Prohibited)
Phase
Phase 3
Recruitment status
Withdrawn
Sponsor
RWTH Aachen University
Enrollment
0
Start date
Nov 2020
Locations
1 site, Germany
Primary endpoint
Changes in the metabolomics profile (fold changes) between Liraglutide treatment group and placebo group after 1 and 3 months
View Liraglutide compound reference